Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Short term Debt (2021 - 2025)

Historic Short term Debt for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $18.0 million.

  • Indivior Pharmaceuticals' Short term Debt changed N/A to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year change of. This contributed to the annual value of $18.0 million for FY2024, which is 50000.0% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Short term Debt of $18.0 million as of Q3 2025.
  • Indivior Pharmaceuticals' Short term Debt's 5-year high stood at $18.0 million during Q4 2024, with a 5-year trough of $3.0 million in Q4 2021.
  • Moreover, its 5-year median value for Short term Debt was $18.0 million (2024), whereas its average is $11.6 million.
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Short term Debt changed by 0.0% in 2022, and later soared by 50000.0% in 2024.
  • Over the past 5 years, Indivior Pharmaceuticals' Short term Debt (Quarter) stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023, then surged by 500.0% to $18.0 million in 2024, then changed by 0.0% to $18.0 million in 2025.
  • Its Short term Debt was $18.0 million in Q3 2025, compared to $18.0 million in Q2 2025 and $18.0 million in Q1 2025.